Mood Disorders News

A longitudinal study assessing illness progression in patients with bipolar disorder and major depressive disorder found a worsening of patient function with depressive episodes, but an overall improvement in functioning over 5 years.

Alkermes has announced that its schizophrenia/bipolar 1 disorder treatment Lybalvi is now available by prescription in the U.S.

Depressive symptoms and clinically significant depression were frequent more than 12 weeks after SARS-CoV-2 infection, according to a systematic review published in Journal of Psychiatric Research.

Measurement-based care decreased depression severity, promoted remission and improved medication adherence among patients with depressive disorders treated with pharmacotherapy, according to a study.

Diagnostic shifts related to bipolar disorder were common, particularly for other affective disorders, according to results of a longitudinal study published in Journal of Clinical Psychiatry.

U.S. adults with a major depressive episode and suicidal ideation or behavior with intent had higher mental health care resource utilization and more barriers to care than those with only a major depressive episode.

Caplyta reduced depression symptoms in patients with major depressive episodes linked to bipolar I and bipolar II disorders, according to a phase 3 randomized placebo-controlled trial in American Journal of Psychiatry.

In randomized clinical trials, participants with treatment-resistant major depression experienced a large placebo effect across all treatment modalities, according to a meta-analysis in JAMA Network Open.

People from historically underrepresented groups with depression symptoms more often expressed wanting a provider who shared or understood their culture, according to a retrospective, population-based, cross-sectional study in Lancet Psychiatry.

People with affective disorders had the highest rates of nosocomial PTSD 3 months after discharge from psychiatric hospitalization, according to a study in Psychiatry Research.